https://iceni.substack.com/p/modernas-mrna-mystery Not-So-Humble Beginnings
In 2013, ModeRNA and AstraZeneca signed a five-year agreement to develop and commercialize mRNA-based therapies for cardiovascular, metabolic, and renal diseases, as well as cancer. As part of this agreement, AstraZeneca paid $240 million dollars to ModeRNA, despite them, again, having no commercial products nor ongoing drug trials.
Also in 2013, ModeRNA was awarded $25 million from DARPA to develop mRNA-based therapies. Given that DARPA are a military think tank involved in biosecurity/biosurveillance/biodefense, this was an odd fit, considering that ModeRNA were, at the time, engaged in research for cancer therapies and treating chronic illnesses with mRNA, and not mRNA vaccines, which have a clear biodefense purpose (i.e. rapidly vaccinating against bioweapons). ModeRNA are based in Cambridge, Massachusetts. Incidentally, a large portion of the US biodefense network is also situated in the vicinity of Boston, as outlined in Frank L. Smith’s book, American Biodefense
In 2014, Alexion Pharmaceuticals struck a deal with ModeRNA, paying them $100 million to develop treatments for rare diseases, including Crigler-Najjar syndrome. The program was terminated in 2017 after animal testing showed that the therapies would never be safe enough to enter human trials
In 2017, ModeRNA tested their mRNA tech on Sprague-Dawley rats and cynomolgus monkeys at Charles River Laboratories’ facilities. They found that the mRNA spread well beyond the injection site and was discovered in the liver, spleen, bone marrow, and heart
In 2018, ModeRNA rebranded themselves as Moderna Inc., and raised $621 million through their IPO by the end of that year.
Through the end of 2019, Moderna had accumulated losses of $1.5 billion dollars over the course of the company’s history.
Paradoxically, they continued to excite investors.
Very shortly after China sent the sequence for 2019-nCoV - which would eventually become known as SARS-CoV-2 - on January 11th, 2020, Moderna claimed to have developed a vaccine within 48 hours of receiving the gene sequence for the virus, on January 13th.
You may be surprised to learn that of the trio of long-awaited coronavirus vaccines, the most promising, Moderna’s mRNA-1273, which reported a 94.5 percent efficacy rate on November 16, had been designed by January 13. This was just two days after the genetic sequence had been made public in an act of scientific and humanitarian generosity that resulted in China’s Yong-Zhen Zhang’s being temporarily forced out of his lab. In Massachusetts, the Moderna vaccine design took all of one weekend. It was completed before China had even acknowledged that the disease could be transmitted from human to human, more than a week before the first confirmed coronavirus case in the United States. By the time the first American death was announced a month later, the vaccine had already been manufactured and shipped to the National Institutes of Health for the beginning of its Phase I clinical trial. This is — as the country and the world are rightly celebrating — the fastest timeline of development in the history of vaccines. It also means that for the entire span of the pandemic in this country, which has already killed more than 250,000 Americans, we had the tools we needed to prevent it.
As Norbert Pardi, an mRNA vaccine scientist at the University of Pennsylvania, puts it, we’re “very lucky, actually,” that scientists worked out the 2P mutation for a MERS vaccine before the COVID-19 pandemic. “It wouldn’t be possible to go so fast with the Moderna vaccine otherwise.”
Other companies, including Johnson & Johnson, Novavax, and Pfizer, are hoping the 2P mutation works for their COVID-19 vaccines too.
The 2P mutation might quite literally be the smallest detail that could make or break the first generation of COVID-19 vaccines. It’s an easy enough tweak to add during the early stages of vaccine design. And if successful, 2P-based vaccines may herald a new generation of vaccines whose molecular makeup is fine-tuned to craft a safer, stronger immune response.
Research into 2P Spike existed before the COVID-19 outbreak, with other coronaviruses; it was not an innovation specific to COVID-19 vaccines, but merely repurposed for them.
The conceit here was that the vaccine would stay in the shoulder and would not pose
any issues for any of the subject’s organs. However, we know from Moderna’s prior research (and the leaked Pfizer biodistribution documents) that lipid nanoparticles spread all over the body, affecting the heart, liver, spleen, bone marrow, and other key tissues. Therefore, the notion that the vaccine would remain in the deltoid muscle of the recipient was always a blatant falsehood.
Moderna was able to secure considerable funding from HHS and BARDA under Operation Warp Speed, to develop a COVID-19 vaccine. They pushed the vaccine through highly accelerated trials with a very questionable methodology. Governments signed purchase agreements with these companies that waived their legal liability in case anything went wrong
In Moderna’s case, this is highly alarming, considering that mRNA-1273 is their first-ever commercial product. Imagine if there was a car company that was funded by angel investors and military think tanks for years and years, and the government mandated that everyone in the country must purchase one of these cars on pain of job loss and ostracization if they refuse, and the company producing the cars had no legal liability at all, such that if the wheels fell off and the vehicle flipped over and you broke your neck, you would have no recourse to sue the manufacturer. That’s what our governments agreed on with Moderna, for an unsafe gene therapy drug masquerading as a vaccine.
There are many, many issues with these so-called vaccines, with toxicity, long-term side effects, and potential undisclosed ingredients, as outlined in our prior articles on the matter. They should never have been approved by the FDA.